In Phase C, individuals will get ABBV-744 and oral navitoclax. In Segment D, individuals will obtain ABBV-744 and ruxolitinib. Participants will get treatment until eventually disease progression or the contributors are unable to tolerate the study drugs. - Participant consumed grapefruit or grapefruit solutions within three times before the main https://judahbnxir.blogoxo.com/32214957/a-simple-key-for-abbv-744-brd4-inhibition-in-cancer-cell-lines-unveiled